Most Read Articles
Audrey Abella, 03 Sep 2020
Interim analyses of the INBUILD trial presented at ATS 2020 continue to reflect the benefit of the tyrosine kinase inhibitor nintedanib for individuals with progressive fibrosing interstitial lung diseases (ILDs).
Roshini Claire Anthony, 18 Jul 2020

The concurrent occurrence of diabesity and COVID-19 may lead to more severe disease due to the latter, according to a presentation at the Opening Session of ENDO Online.

Pearl Toh, 2 days ago
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.

Low BMI, high PaCO2 predict 90-day mortality in severe COPD

27 Jul 2019

High partial pressure of carbon dioxide (PaCO2) and age, low body mass index (BMI), and previous admission for exacerbations of chronic obstructive pulmonary disease (ECOPD) in the last 2 years strongly predict 90-day mortality in patients with severe COPD, according to the Classification and Regression Tree (CART) analysis of a recent study.

“In absence of any of these factors, no patients died, suggesting that this model indeed enables risk stratification,” the authors said.

In total, 364 hospitalized patients (mean age, 70.5 years; 54.4 percent male; mean forced expiratory volume in 1 s [FEV1], 45.2 percent of predicted) were included in the analysis. The rate of in-hospital mortality was 8.5 percent and 90-day mortality 16.2 percent.

The following factors independently predicted 90-day mortality: PaCO2 (odds ratio [OR], 1.31, 95 percent CI, 1.00–0.35), age (OR, 1.09, 0.06–0.11), BMI <18.5 kg/m2 (OR, 2.72, 0.53–1.47) and previous admission for ECOPD in the last 2 years (OR, 1.29, –0.14 to –0.65). According to the CART model, the most discriminatory factors were PaCO2 ≥9.1 kPa, age >80 years, BMI <18.5 kg/m2 and previous admission for ECOPD.

“ECOPD [is] associated with increased in‐hospital and short‐term mortality,” the authors said. “Developing an easy‐to‐use model to predict adverse outcomes will be useful in daily clinical practice and will facilitate management decisions.”

This retrospective, observational, cohort study enrolled all patients with ECOPD admitted to Maastricht University Medical Center between June 2011 and December 2014. The authors considered the last admission and recorded its demographic, clinical and biochemical data.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 03 Sep 2020
Interim analyses of the INBUILD trial presented at ATS 2020 continue to reflect the benefit of the tyrosine kinase inhibitor nintedanib for individuals with progressive fibrosing interstitial lung diseases (ILDs).
Roshini Claire Anthony, 18 Jul 2020

The concurrent occurrence of diabesity and COVID-19 may lead to more severe disease due to the latter, according to a presentation at the Opening Session of ENDO Online.

Pearl Toh, 2 days ago
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.